MVA-EBNA1/LMP2 Vaccine

[Jusontin]

Vaccine name: MVA-EBNA1/LMP2 Vaccine
Type: Recombinant vector vaccine
Status: Clinical trial
Host Species: Human
Description: A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the gene for the CD4 epitope-rich C-terminal domain of the Epstein Barr Virus (EBV) antigen EBNA1 and fused to the full-length of the EBV-associated antigen latent membrane protein 2 (LMP2), with potential immunostimulatory and antineoplastic activities. Upon administration, MVA EBNA1/LMP2 vaccine may elicit a cytotoxic T-cell immune response against cancer cells expressing EBNA1 and LMP2. Multi-antigen vaccine therapy may be more efficacious than single-antigen therapy vaccine therapy. EBNA1, a sequence-specific DNA binding protein, plays an important role in EBV episomal genome maintenance and gene transactivation. (NCIT_C91076).
Immunization Route: n/a
PubMed: n/a
PumMed Link: n/a
Gene/protein: n/a
VIOLIN Link: http://www.violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5314&keywords=MVA-EBNA1/LMP2%20Vaccine

[yuanyp19]

Added to VO:
http://purl.obolibrary.org/obo/VO_0005451
It will be shown in our next VO release.